



Doribax® (doripenem) – First-Time Generic

- On December 12, 2016, [Apotex launched](#) an AP-rated generic version of Shionogi's [Doribax \(doripenem\)](#) injection, for the treatment of complicated intra-abdominal infections and complicated urinary-tract infections, including pyelonephritis, caused by designated susceptible bacteria.
 - To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doribax and other antibacterial drugs, Doribax should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
 - When culture and susceptibility information are available, they should be considered in selecting and modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.